Citadel Advisors’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
Other funds holding CSBR
BMC
NMC
TAM
MBAM
Citadel Advisors's CSBR Position: Q2 2026 in Review
Citadel Advisors opened a new position in Champions Oncology (CSBR) in Q2 2026: 18,295 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #12602 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CSBR as recently as Q3 2025.
Citadel Advisors first reported a position in CSBR in Q3 2016 and has held it in 15 quarters since. The position peaked at $280K in Q3 2022. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.
- Citadel Advisors held 18,295 shares of Champions Oncology worth $113K as of Q2 2026.
- Champions Oncology was a new Citadel Advisors position in Q2 2026.
- Champions Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12602 holding.
- Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and has held it in 15 quarters since.
- Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
- 28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.